209 related articles for article (PubMed ID: 24766820)
1. A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7.
Fox CB; Sivananthan SJ; Duthie MS; Vergara J; Guderian JA; Moon E; Coblentz D; Reed SG; Carter D
J Nanobiotechnology; 2014 Apr; 12():17. PubMed ID: 24766820
[TBL] [Abstract][Full Text] [Related]
2. Co-encapsulation of synthetic lipidated TLR4 and TLR7/8 agonists in the liposomal bilayer results in a rapid, synergistic enhancement of vaccine-mediated humoral immunity.
Short KK; Miller SM; Walsh L; Cybulski V; Bazin H; Evans JT; Burkhart D
J Control Release; 2019 Dec; 315():186-196. PubMed ID: 31654684
[TBL] [Abstract][Full Text] [Related]
3. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
[TBL] [Abstract][Full Text] [Related]
4. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.
Orr MT; Fox CB; Baldwin SL; Sivananthan SJ; Lucas E; Lin S; Phan T; Moon JJ; Vedvick TS; Reed SG; Coler RN
J Control Release; 2013 Nov; 172(1):190-200. PubMed ID: 23933525
[TBL] [Abstract][Full Text] [Related]
6. Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01.
Wilkinson A; Lattmann E; Roces CB; Pedersen GK; Christensen D; Perrie Y
J Control Release; 2018 Dec; 291():1-10. PubMed ID: 30291987
[TBL] [Abstract][Full Text] [Related]
7. Conjugation of a Small-Molecule TLR7 Agonist to Silica Nanoshells Enhances Adjuvant Activity.
Huang CH; Mendez N; Echeagaray OH; Weeks J; Wang J; Vallez CN; Gude N; Trogler WC; Carson DA; Hayashi T; Kummel AC
ACS Appl Mater Interfaces; 2019 Jul; 11(30):26637-26647. PubMed ID: 31276378
[TBL] [Abstract][Full Text] [Related]
8. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
Vasilakos JP; Tomai MA
Expert Rev Vaccines; 2013 Jul; 12(7):809-19. PubMed ID: 23885825
[TBL] [Abstract][Full Text] [Related]
9. Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod.
Othoro C; Johnston D; Lee R; Soverow J; Bystryn JC; Nardin E
Infect Immun; 2009 Feb; 77(2):739-48. PubMed ID: 19047411
[TBL] [Abstract][Full Text] [Related]
10. Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-γ.
Desbien AL; Reed SJ; Bailor HR; Dubois Cauwelaert N; Laurance JD; Orr MT; Fox CB; Carter D; Reed SG; Duthie MS
Eur J Immunol; 2015 Feb; 45(2):407-17. PubMed ID: 25367751
[TBL] [Abstract][Full Text] [Related]
11. TLR8 combined withTLR3 or TLR4 agonists enhances DC-NK driven effector Tc1 cells.
Nouri-Shirazi M; Tamjidi S; Nourishirazi E; Guinet E
Immunol Lett; 2018 Jan; 193():58-66. PubMed ID: 29103998
[TBL] [Abstract][Full Text] [Related]
12. Effective Combination Adjuvants Engage Both TLR and Inflammasome Pathways To Promote Potent Adaptive Immune Responses.
Seydoux E; Liang H; Dubois Cauwelaert N; Archer M; Rintala ND; Kramer R; Carter D; Fox CB; Orr MT
J Immunol; 2018 Jul; 201(1):98-112. PubMed ID: 29769270
[TBL] [Abstract][Full Text] [Related]
13. TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses.
Fox CB; Moutaftsi M; Vergara J; Desbien AL; Nana GI; Vedvick TS; Coler RN; Reed SG
Vaccine; 2013 Dec; 31(49):5848-55. PubMed ID: 24120675
[TBL] [Abstract][Full Text] [Related]
14. A TLR7/8 Agonist-Including DOEPC-Based Cationic Liposome Formulation Mediates Its Adjuvanticity Through the Sustained Recruitment of Highly Activated Monocytes in a Type I IFN-Independent but NF-κB-Dependent Manner.
Auderset F; Belnoue E; Mastelic-Gavillet B; Lambert PH; Siegrist CA
Front Immunol; 2020; 11():580974. PubMed ID: 33262759
[TBL] [Abstract][Full Text] [Related]
15. Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica.
Abhyankar MM; Noor Z; Tomai MA; Elvecrog J; Fox CB; Petri WA
Vaccine; 2017 Feb; 35(6):916-922. PubMed ID: 28089548
[TBL] [Abstract][Full Text] [Related]
16. Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice.
Zhang WW; Matlashewski G
Infect Immun; 2008 Aug; 76(8):3777-83. PubMed ID: 18474642
[TBL] [Abstract][Full Text] [Related]
17. TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines.
Johnston D; Zaidi B; Bystryn JC
Cancer Immunol Immunother; 2007 Aug; 56(8):1133-41. PubMed ID: 17139492
[TBL] [Abstract][Full Text] [Related]
18. TLR4 and TLR7/8 Adjuvant Combinations Generate Different Vaccine Antigen-Specific Immune Outcomes in Minipigs when Administered via the ID or IN Routes.
McKay PF; King DF; Mann JF; Barinaga G; Carter D; Shattock RJ
PLoS One; 2016; 11(2):e0148984. PubMed ID: 26862758
[TBL] [Abstract][Full Text] [Related]
19. Mast cells are crucial for early inflammation, migration of Langerhans cells, and CTL responses following topical application of TLR7 ligand in mice.
Heib V; Becker M; Warger T; Rechtsteiner G; Tertilt C; Klein M; Bopp T; Taube C; Schild H; Schmitt E; Stassen M
Blood; 2007 Aug; 110(3):946-53. PubMed ID: 17446350
[TBL] [Abstract][Full Text] [Related]
20. Age-Specific Adjuvant Synergy: Dual TLR7/8 and Mincle Activation of Human Newborn Dendritic Cells Enables Th1 Polarization.
van Haren SD; Dowling DJ; Foppen W; Christensen D; Andersen P; Reed SG; Hershberg RM; Baden LR; Levy O
J Immunol; 2016 Dec; 197(11):4413-4424. PubMed ID: 27793997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
